- Home
- CLEU vs MURA Comparison
CLEU vs MURA Comparison
Compare CLEU & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- MURA
- Stock Information
- Founded
- CLEU 2011
- MURA 2013
- Country
- CLEU China
- MURA Ireland
- Employees
- CLEU N/A
- MURA N/A
- Industry
- CLEU Other Consumer Services
- MURA
- Sector
- CLEU Real Estate
- MURA
- Exchange
- CLEU Nasdaq
- MURA Nasdaq
- Market Cap
- CLEU 20.0M
- MURA 17.7M
- IPO Year
- CLEU 2020
- MURA N/A
- Fundamental
- Price
- CLEU $1.28
- MURA $2.48
- Analyst Decision
- CLEU
- MURA Strong Buy
- Analyst Count
- CLEU 0
- MURA 4
- Target Price
- CLEU N/A
- MURA $13.00
- AVG Volume (30 Days)
- CLEU 64.9K
- MURA 1.1M
- Earning Date
- CLEU 01-01-0001
- MURA 05-20-2025
- Dividend Yield
- CLEU N/A
- MURA N/A
- EPS Growth
- CLEU N/A
- MURA N/A
- EPS
- CLEU N/A
- MURA N/A
- Revenue
- CLEU $2,413,409.00
- MURA N/A
- Revenue This Year
- CLEU N/A
- MURA $34.35
- Revenue Next Year
- CLEU N/A
- MURA N/A
- P/E Ratio
- CLEU N/A
- MURA N/A
- Revenue Growth
- CLEU N/A
- MURA N/A
- 52 Week Low
- CLEU $0.05
- MURA $0.95
- 52 Week High
- CLEU $7.90
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- CLEU 39.77
- MURA 50.99
- Support Level
- CLEU $1.80
- MURA $2.48
- Resistance Level
- CLEU $2.37
- MURA $2.72
- Average True Range (ATR)
- CLEU 0.16
- MURA 0.10
- MACD
- CLEU -0.05
- MURA 0.00
- Stochastic Oscillator
- CLEU 9.18
- MURA 13.22
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.